Immunizing Patients with Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or Gp100 Melanoma Antigens

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 1998 Dec 23

PMID 9862627

Citations 72

Authors

S A Rosenberg

Y Zhai

J C Yang

D J Schwartzentruber

P Hwu

F M Marincola

S L Topalian

N P Restifo

C A Seipp

J H Einhorn

B Roberts

D E White

Affiliations

Soon will be listed here.

Abstract

Background: The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilities for the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations.

Methods: In phase I studies, 54 patients received escalating doses (between 10(7) and 10(11) plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed.

Results: Recombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed no consistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing antibody were found in the pretreatment sera of the patients.

Conclusions: High doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing antibody present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens.

Citing Articles

Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.

Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S Pharmaceutics. 2025; 17(2).

PMID: 40006583 PMC: 11859086. DOI: 10.3390/pharmaceutics17020216.

The Evolving T Cell Receptor Recognition Code: The Rules Are More Like Guidelines.

Gray G, Chukwuma P, Eldaly B, Perera W, Brambley C, Rosales T Immunol Rev. 2025; 329(1):e13439.

PMID: 39804137 PMC: 11771984. DOI: 10.1111/imr.13439.

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.

Al Hmada Y, Brodell R, Kharouf N, Flanagan T, Alamodi A, Hassan S Cancers (Basel). 2024; 16(2).

PMID: 38275910 PMC: 10814963. DOI: 10.3390/cancers16020470.

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8 T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Zheng Y, Lu Z, Ding J, Jiang N, Wang J, Yang J Cancers (Basel). 2022; 14(18).

PMID: 36139670 PMC: 9497125. DOI: 10.3390/cancers14184512.

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Ku M, Authie P, Bourgine M, Anna F, Noirat A, Moncoq F EMBO Mol Med. 2021; 13(12):e14459.

PMID: 34647691 PMC: 8646827. DOI: 10.15252/emmm.202114459.

References

Rosenberg S, Yannelli J, Yang J, Topalian S, Schwartzentruber D, Weber J . Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994; 86(15):1159-66. DOI: 10.1093/jnci/86.15.1159. View

Crystal R, McElvaney N, Rosenfeld M, Chu C, Mastrangeli A, Hay J . Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994; 8(1):42-51. DOI: 10.1038/ng0994-42. View

Yang Y, Ertl H, Wilson J . MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994; 1(5):433-42. DOI: 10.1016/1074-7613(94)90074-4. View

Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S . Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995; 154(8):3961-8. View

Bronte V, Tsung K, Rao J, Chen P, Wang M, Rosenberg S . IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 1995; 154(10):5282-92. PMC: 2041892. View

Yei S, Mittereder N, Tang K, OSullivan C, Trapnell B . Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1994; 1(3):192-200. View

Ueno H, Li J, Tomita H, Yamamoto H, Pan Y, Kanegae Y . Quantitative analysis of repeat adenovirus-mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol. 1995; 15(12):2246-53. DOI: 10.1161/01.atv.15.12.2246. View

Van Pel A, van der Bruggen P, Coulie P, Brichard V, Lethe B, Van den Eynde B . Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 1995; 145:229-50. DOI: 10.1111/j.1600-065x.1995.tb00084.x. View

Chen P, Wang M, Bronte V, Zhai Y, Rosenberg S, Restifo N . Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol. 1996; 156(1):224-31. PMC: 1950465. View

10.

Imler J . Adenovirus vectors as recombinant viral vaccines. Vaccine. 1995; 13(13):1143-51. DOI: 10.1016/0264-410x(95)00032-v. View

11.

Zhai Y, Yang J, Kawakami Y, Spiess P, Wadsworth S, Cardoza L . Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J Immunol. 1996; 156(2):700-10. View

12.

Salgaller M, Marincola F, Cormier J, Rosenberg S . Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 1996; 56(20):4749-57. View

13.

Kaplan J, St George J, Pennington S, Keyes L, Johnson R, Wadsworth S . Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 1996; 3(2):117-27. View

14.

Yang Y, Jooss K, Su Q, Ertl H, Wilson J . Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996; 3(2):137-44. View

15.

Leinwand L, Gall J, Bloom B . Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 1996; 3(2):154-62. View

16.

Marincola F, Rivoltini L, Salgaller M, Player M, Rosenberg S . Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol. 1996; 19(4):266-77. DOI: 10.1097/00002371-199607000-00003. View

17.

Rosenberg S . Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 1996; 88(22):1635-44. DOI: 10.1093/jnci/88.22.1635. View

18.

Mack C, Song W, Carpenter H, Wickham T, Kovesdi I, HARVEY B . Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther. 1997; 8(1):99-109. DOI: 10.1089/hum.1997.8.1-99. View

19.

Schulick A, Vassalli G, Dunn P, Dong G, Rade J, Zamarron C . Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 1997; 99(2):209-19. PMC: 507788. DOI: 10.1172/JCI119149. View

20.

Kawakami Y, Eliyahu S, Delgado C, Robbins P, Sakaguchi K, Appella E . Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994; 91(14):6458-62. PMC: 44221. DOI: 10.1073/pnas.91.14.6458. View